Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

WVVI vs NBY

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
WVVI
Willamette Valley Vineyards, Inc.

Beverages - Wineries & Distilleries

Consumer DefensiveNASDAQ • US
Market Cap$14M
5Y Perf.-53.5%
NBY
NovaBay Pharmaceuticals, Inc.

Biotechnology

HealthcareAMEX • US
Market Cap$11M
5Y Perf.-100.0%

WVVI vs NBY — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
WVVI logoWVVI
NBY logoNBY
IndustryBeverages - Wineries & DistilleriesBiotechnology
Market Cap$14M$11M
Revenue (TTM)$37M$3M
Net Income (TTM)$-1M$3M
Gross Margin60.5%54.6%
Operating Margin-2.4%-273.0%
Total Debt$15.52B$2M
Cash & Equiv.$411M$430K

WVVI vs NBYLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

WVVI
NBY
StockMay 20May 26Return
Willamette Valley V… (WVVI)10046.5-53.5%
NovaBay Pharmaceuti… (NBY)1000.0-100.0%

Price return only. Dividends and distributions are not included.

Quick Verdict: WVVI vs NBY

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: NBY leads in 4 of 5 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Willamette Valley Vineyards, Inc. is the stronger pick specifically for dividend income and shareholder returns. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
WVVI
Willamette Valley Vineyards, Inc.
The Long-Run Compounder

WVVI is the clearest fit if your priority is long-term compounding and sleep-well-at-night.

  • -60.8% 10Y total return vs NBY's -100.0%
  • Lower volatility, beta -0.25, Low D/E 23.4%, current ratio 2.70x
  • Beta -0.25, yield 100.0%, current ratio 2.70x
Best for: long-term compounding and sleep-well-at-night
NBY
NovaBay Pharmaceuticals, Inc.
The Growth Play

NBY carries the broadest edge in this set and is the clearest fit for growth exposure.

  • Rev growth -6.4%, EPS growth 98.2%, 3Y rev CAGR -1.4%
  • -6.4% revenue growth vs WVVI's -100.0%
  • 114.6% margin vs WVVI's -3.3%
Best for: growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthNBY logoNBY-6.4% revenue growth vs WVVI's -100.0%
Quality / MarginsNBY logoNBY114.6% margin vs WVVI's -3.3%
DividendsWVVI logoWVVI100.0% yield; 4-year raise streak; the other pay no meaningful dividend
Momentum (1Y)NBY logoNBY+102.8% vs WVVI's -53.3%
Efficiency (ROA)NBY logoNBY93.0% ROA vs WVVI's -1.1%, ROIC -217.0% vs -2.6%

WVVI vs NBY — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

WVVIWillamette Valley Vineyards, Inc.

Segment breakdown not available.

NBYNovaBay Pharmaceuticals, Inc.
FY 2024
Total Product Revenue
100.0%$10M

WVVI vs NBY — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLWVVILAGGINGNBY

Income & Cash Flow (Last 12 Months)

WVVI leads this category, winning 4 of 6 comparable metrics.

WVVI is the larger business by revenue, generating $37M annually — 13.2x NBY's $3M. NBY is the more profitable business, keeping 114.6% of every revenue dollar as net income compared to WVVI's -3.3%. On growth, WVVI holds the edge at -10.9% YoY revenue growth, suggesting stronger near-term business momentum.

MetricWVVI logoWVVIWillamette Valley…NBY logoNBYNovaBay Pharmaceu…
RevenueTrailing 12 months$37M$3M
EBITDAEarnings before interest/tax$2M-$8M
Net IncomeAfter-tax profit-$1M$3M
Free Cash FlowCash after capex-$3M-$7M
Gross MarginGross profit ÷ Revenue+60.5%+54.6%
Operating MarginEBIT ÷ Revenue-2.4%-2.7%
Net MarginNet income ÷ Revenue-3.3%+114.6%
FCF MarginFCF ÷ Revenue-8.5%-2.5%
Rev. Growth (YoY)Latest quarter vs prior year-10.9%-78.7%
EPS Growth (YoY)Latest quarter vs prior year-94.1%+63.3%
WVVI leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

WVVI leads this category, winning 1 of 1 comparable metric.
MetricWVVI logoWVVIWillamette Valley…NBY logoNBYNovaBay Pharmaceu…
Market CapShares × price$14M$11M
Enterprise ValueMkt cap + debt − cash$15.1B$13M
Trailing P/EPrice ÷ TTM EPS-4.39x-0.74x
Forward P/EPrice ÷ next-FY EPS est.
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple
Price / SalesMarket cap ÷ Revenue1.16x
Price / BookPrice ÷ Book value/share0.00x
Price / FCFMarket cap ÷ FCF
WVVI leads this category, winning 1 of 1 comparable metric.

Profitability & Efficiency

NBY leads this category, winning 5 of 8 comparable metrics.

NBY delivers a 198.5% return on equity — every $100 of shareholder capital generates $198 in annual profit, vs $-2 for WVVI. On the Piotroski fundamental quality scale (0–9), NBY scores 3/9 vs WVVI's 1/9, reflecting mixed financial health.

MetricWVVI logoWVVIWillamette Valley…NBY logoNBYNovaBay Pharmaceu…
ROE (TTM)Return on equity-1.8%+198.5%
ROA (TTM)Return on assets-1.1%+93.0%
ROICReturn on invested capital-2.6%-2.2%
ROCEReturn on capital employed-3.1%-2.2%
Piotroski ScoreFundamental quality 0–913
Debt / EquityFinancial leverage0.23x
Net DebtTotal debt minus cash$15.1B$1M
Cash & Equiv.Liquid assets$411M$430,000
Total DebtShort + long-term debt$15.5B$2M
Interest CoverageEBIT ÷ Interest expense-0.69x-89.97x
NBY leads this category, winning 5 of 8 comparable metrics.

Total Returns (Dividends Reinvested)

WVVI leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in WVVI five years ago would be worth $1,807 today (with dividends reinvested), compared to $13 for NBY. Over the past 12 months, NBY leads with a +102.8% total return vs WVVI's -53.3%. The 3-year compound annual growth rate (CAGR) favors WVVI at -21.9% vs NBY's -67.4% — a key indicator of consistent wealth creation.

MetricWVVI logoWVVIWillamette Valley…NBY logoNBYNovaBay Pharmaceu…
YTD ReturnYear-to-date-11.4%-93.6%
1-Year ReturnPast 12 months-53.3%+102.8%
3-Year ReturnCumulative with dividends-52.5%-96.5%
5-Year ReturnCumulative with dividends-81.9%-99.9%
10-Year ReturnCumulative with dividends-60.8%-100.0%
CAGR (3Y)Annualised 3-year return-21.9%-67.4%
WVVI leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

WVVI leads this category, winning 2 of 2 comparable metrics.

WVVI is the less volatile stock with a -0.25 beta — it tends to amplify market swings less than NBY's 2.43 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. WVVI currently trades 39.1% from its 52-week high vs NBY's 1.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricWVVI logoWVVIWillamette Valley…NBY logoNBYNovaBay Pharmaceu…
Beta (5Y)Sensitivity to S&P 500-0.25x2.43x
52-Week HighHighest price in past year$7.18$99.75
52-Week LowLowest price in past year$2.49$1.11
% of 52W HighCurrent price vs 52-week peak+39.1%+1.9%
RSI (14)Momentum oscillator 0–10059.742.5
Avg Volume (50D)Average daily shares traded3K592K
WVVI leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

WVVI is the only dividend payer here at 100.00% yield — a key consideration for income-focused portfolios.

MetricWVVI logoWVVIWillamette Valley…NBY logoNBYNovaBay Pharmaceu…
Analyst RatingConsensus buy/hold/sell
Price TargetConsensus 12-month target
# AnalystsCovering analysts
Dividend YieldAnnual dividend ÷ price+100.0%
Dividend StreakConsecutive years of raises4
Dividend / ShareAnnual DPS$194.20
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

WVVI leads in 4 of 6 categories (Income & Cash Flow, Valuation Metrics). NBY leads in 1 (Profitability & Efficiency).

Best OverallWillamette Valley Vineyards… (WVVI)Leads 4 of 6 categories
Loading custom metrics...

WVVI vs NBY: Frequently Asked Questions

8 questions · data-driven answers · updated daily

01

Is WVVI or NBY a better buy right now?

For growth investors, NovaBay Pharmaceuticals, Inc.

(NBY) is the stronger pick with -6. 4% revenue growth year-over-year, versus -100. 0% for Willamette Valley Vineyards, Inc. (WVVI). The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — WVVI or NBY?

Over the past 5 years, Willamette Valley Vineyards, Inc.

(WVVI) delivered a total return of -81. 9%, compared to -99. 9% for NovaBay Pharmaceuticals, Inc. (NBY). Over 10 years, the gap is even starker: WVVI returned -60. 8% versus NBY's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — WVVI or NBY?

By beta (market sensitivity over 5 years), Willamette Valley Vineyards, Inc.

(WVVI) is the lower-risk stock at -0. 25β versus NovaBay Pharmaceuticals, Inc. 's 2. 43β — meaning NBY is approximately -1067% more volatile than WVVI relative to the S&P 500.

04

Which is growing faster — WVVI or NBY?

By revenue growth (latest reported year), NovaBay Pharmaceuticals, Inc.

(NBY) is pulling ahead at -6. 4% versus -100. 0% for Willamette Valley Vineyards, Inc. (WVVI). On earnings-per-share growth, the picture is similar: NovaBay Pharmaceuticals, Inc. grew EPS 98. 2% year-over-year, compared to -33. 3% for Willamette Valley Vineyards, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — WVVI or NBY?

Willamette Valley Vineyards, Inc.

(WVVI) is the more profitable company, earning -3. 3% net margin versus -73. 8% for NovaBay Pharmaceuticals, Inc. — meaning it keeps -3. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: WVVI leads at -2. 4% versus -59. 7% for NBY. At the gross margin level — before operating expenses — NBY leads at 66. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Which pays a better dividend — WVVI or NBY?

In this comparison, WVVI (100.

0% yield) pays a dividend. NBY does not pay a meaningful dividend and should not be held primarily for income.

07

Is WVVI or NBY better for a retirement portfolio?

For long-horizon retirement investors, Willamette Valley Vineyards, Inc.

(WVVI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 25), 100. 0% yield). NovaBay Pharmaceuticals, Inc. (NBY) carries a higher beta of 2. 43 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (WVVI: -60. 8%, NBY: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

08

What are the main differences between WVVI and NBY?

These companies operate in different sectors (WVVI (Consumer Defensive) and NBY (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: WVVI is a small-cap income-oriented stock; NBY is a small-cap quality compounder stock. WVVI pays a dividend while NBY does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

WVVI

Income & Dividend Stock

  • Sector: Consumer Defensive
  • Market Cap > $100B
  • Gross Margin > 36%
  • Dividend Yield > 40.0%
Run This Screen
Stocks Like

NBY

Quality Mega-Cap Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 68%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform WVVI and NBY on the metrics below

Revenue Growth>
%
(WVVI: -10.9% · NBY: -78.7%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.